Quantcast

Latest Clinical trial Stories

2014-06-26 16:23:38

Paper Addresses Challenges and Explores Opportunities to Stimulate Repurposing of FDA-Approved Drugs for Alzheimer's, Parkinson's and Related Diseases NEW YORK, June 26, 2014 /PRNewswire-USNewswire/ -- A new peer-reviewed publication from the Alzheimer's Drug Discovery Foundation (ADDF) and The Michael J. Fox Foundation for Parkinson's Research (MJFF) offers strategic insight on how philanthropy, industry and government organizations can advance repurposing of U.S. Food and Drug...

2014-06-26 08:28:23

-Contributions advancing AD clinical trials to be highlighted in a series of diverse presentations- NEWTOWN, Pa., June 26, 2014 /PRNewswire/ -- BioClinica(®), Inc., the world's leading provider of medical imaging and cardiovascular safety services for the pharmaceutical, biotechnology, and medical device industries, announced today that their neuroscience clinical trial experts will present recent clinical trial progress on the front against Alzheimer's Disease (AD) at this year's...

2014-06-25 23:09:12

This webinar will describe the Translational Pharmaceutics™ platform and present Enabled-First-in-Human case studies to illustrate how it has been applied in early stage drug development programs. There will be two live broadcasts on Wednesday July 9, 2014, at 9am EDT/2pm BST, and at 12pm EDT/5pm BST. Toronto, Canada (PRWEB) June 25, 2014 Enabled-First-in-Human™ programs re-engineer the pathway from candidate selection into clinical development and through to Proof of Concept (PoC)....

2014-06-25 08:30:55

GREENWOOD VILLAGE, Colo., June 25, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has informed the Transplant and Ophthalmology Division of the FDA of its intent to reduce the patient sample size in the OptimEyes Study for the treatment of Diabetic Macular Edema (oral treatment with Optina(TM)). This trial was intended to enroll 450 patients and was powered at 95%. The present enrollment of over 355 patients provides an adequate power of 88%,...

2014-06-24 23:14:00

Cancer Treatment and Wellness Center is one of the first sites in the world to provide patients with access to leading edge breast cancer drug trial PALOMA-3. Westchester County, NY (PRWEB) June 24, 2014 The Cancer Treatment and Wellness Center at Northern Westchester Hospital is now enrolling patients for a clinical research study investigating the use of palbociclib (PD-0332991), a CDK 4/6 inhibitor being investigated for advanced stage breast cancer. CDK proteins can be involved in...

2014-06-24 16:24:29

G-202 Data in HCC Patients (Phase I and Phase II) Highly Suggestive of Positive Clinical Activity SAN ANTONIO, June 24, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International corporate presentation. Chairman and CEO, Craig Dionne, PhD, presented the company overview and clinical trial updates for G-202 at the 2014 BIO International Convention, today, Tuesday, June 24th, at...

2014-06-24 10:00:46

BMJ-British Medical Journal May be time to review current restrictive guidance in UK and elsewhere Prisoners are being unfairly excluded from taking part in potentially beneficial clinical research, on the grounds that it would be too difficult and expensive to do so, indicates a study published online in the Journal of Medical Ethics. And current guidance governing research in prisons is too 'protectionist' and restrictive, denying prisoners the chance to access the same research...

2014-06-23 16:25:24

BRIDGEWATER, N.J., June 23, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the progress of on-going discussions with the U.S. Food and Drug Administration for a planned pivotal Phase 3 randomized controlled trial ("RCT") for Neutrolin® for use in hemodialysis patients with a central venous catheter....

2014-06-23 08:29:39

- Initiates Global Footprint, Diversifies Business, Enhances Long-term Growth Prospects - ANAHEIM, Calif., June 23, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the transaction acquiring rights to Synacthen(®) and Synacthen(®) Depot from Novartis Pharma AG and Novartis AG in certain countries outside the U.S. has now closed. Available in more than forty countries for multiple indications, Synacthen (tetracosactide) is a synthetic 24 amino acid...

2014-06-23 08:27:20

SOUTH SAN FRANCISCO, Calif., June 23, 2014 /PRNewswire/ -- Velocity Pharmaceutical Development, LLC ("VPD") and Tigercat Pharma, Inc., ("Tigercat") announced today that they have met all regulatory requirements from Germany's BfArM to initiate a Phase II clinical trial of VPD-737 (serlopitant) in patients with prurigo nodularis. Separately, VPD is also conducting a Phase II clinical trial in the United States evaluating VPD-737 in patients with chronic pruritus. "Prurigo nodularis...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related